Dasatinib first-line treatment in gastrointestinal stromal tumors. A multi center phase II trial.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 22 Feb 2017
At a glance
- Drugs Dasatinib (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Therapeutic Use
- 17 Feb 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2018.
- 02 Jul 2012 Actual patient number is 47 as reported by ClinicalTrials.gov.
- 02 Jul 2012 Planned end date changed from 1 Dec 2014 to 1 Dec 2016 as reported by ClinicalTrials.gov.